RayKnowChina Research Map
Shortlist0

Not yet recruitingStomach cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

TR115 in ARID1A-Mutated Advanced Solid Tumors

An open trial on stomach cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07793318, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed advanced solid tumor with ARID1A mutation.

    Inclusion criterion 3

  3. Cohort 1: Platinum-resistant ovarian/fallopian tube/peritoneal clear cell carcinoma with disease progression after ≥1 prior platinum-based regimen. Cohort 2: Endometrial cancer with disease progression after ≥1 prior platinum-based regimen and prior immunotherapy failure or intolerance. Cohort 3: Other advanced solid tumors (including gastric cancer, urothelial carcinoma) with disease progression after ≥1 prior standard systemic therapy.

    Inclusion criterion 4

    Prior treatment with EZH2 or EZH1/2 inhibitors resulting in disease progression (intolerance permitted).

    Exclusion criterion 1

    Prior anti-tumor therapy-related adverse events not recovered to ≤Grade 1 (CTCAE v6.0), except alopecia or peripheral neuropathy Grade ≤2.

    Exclusion criterion 13

  4. ECOG performance status 0-1.

    Inclusion criterion 5

  5. At least one measurable lesion per RECIST v1.1.

    Inclusion criterion 7

  6. Active hepatitis B or C requiring treatment, or HIV infection.

    Exclusion criterion 8

    Other primary malignancy within 5 years, except cured non-melanoma skin cancer, carcinoma in situ, or thyroid carcinoma.

    Exclusion criterion 12

  7. Male and female participants of childbearing potential must agree to use medically approved contraception during the study and for 6 months after the last dose.

    Inclusion criterion 10

    Pregnancy, lactation, or positive pregnancy test.

    Exclusion criterion 11

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07793318, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Able to understand and provide written informed consent.
  • Age 18 to 70 years, inclusive.
  • Histologically or cytologically confirmed advanced solid tumor with ARID1A mutation.
  • Cohort 1: Platinum-resistant ovarian/fallopian tube/peritoneal clear cell carcinoma with disease progression after ≥1 prior platinum-based regimen. Cohort 2: Endometrial cancer with disease progression after ≥1 prior platinum-based regimen and prior immunotherapy failure or intolerance. Cohort 3: Other advanced solid tumors (including gastric cancer, urothelial carcinoma) with disease progression after ≥1 prior standard systemic therapy.
  • ECOG performance status 0-1.
  • Life expectancy ≥3 months.
  • At least one measurable lesion per RECIST v1.1.
  • Adequate organ function: ANC ≥1.5×10⁹/L, PLT ≥100×10⁹/L, Hb ≥100 g/L (no growth factor or transfusion support within 14 days prior to first dose), TBIL ≤1.5×ULN, ALT/AST ≤2.5×ULN (≤5×ULN if liver metastasis), CrCl ≥50 mL/min, LVEF ≥50%, QTcF <450 ms (male) or <470 ms (female).
  • Willing to provide archival or fresh tumor tissue for biomarker analysis.
  • Male and female participants of childbearing potential must agree to use medically approved contraception during the study and for 6 months after the last dose.

Exclusion Criteria:

  • Prior treatment with EZH2 or EZH1/2 inhibitors resulting in disease progression (intolerance permitted).
  • Third-space fluid accumulation not controllable by drainage or other means.
  • Systemic corticosteroid therapy (>10 mg/day prednisone or equivalent) within 14 days prior to first dose, except for inhaled or topical use.
  • Inability to swallow oral medication or conditions significantly affecting drug absorption.
  • Known central nervous system (CNS) involvement.
  • Tumor invasion or encasement of major vessels.
  • Active infection requiring systemic therapy.
  • Active hepatitis B or C requiring treatment, or HIV infection.
  • Active autoimmune disease requiring systemic immunosuppressive therapy.
  • Significant cardiovascular disease (e.g., myocardial infarction within 6 months, NYHA Class III/IV heart failure, uncontrolled arrhythmia).
  • Pregnancy, lactation, or positive pregnancy test.
  • Other primary malignancy within 5 years, except cured non-melanoma skin cancer, carcinoma in situ, or thyroid carcinoma.
  • Prior anti-tumor therapy-related adverse events not recovered to ≤Grade 1 (CTCAE v6.0), except alopecia or peripheral neuropathy Grade ≤2.
  • Use of strong or moderate CYP3A4 inhibitors/inducers within 14 days prior to first dose.
  • Any other condition that in the investigator's opinion makes the participant unsuitable for the study.

Quoted from ClinicalTrials.gov, NCT07793318, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07793318, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07793318